SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SCHWARTZ NORMAN D
(Last) (First) (Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
(Street)
HERCULES CA 94547
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIOB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chairman, President, and CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Bio-Rad A Common Stock 08/25/2023 M 2,081(1) A $0 429,925 D
Bio-Rad A Common Stock 08/25/2023 F 1,032 D $381.78 428,893 D
Bio-Rad A Common Stock 08/25/2023 M 1,266(1) A $0 430,159 D
Bio-Rad A Common Stock 08/25/2023 F 628 D $381.78 429,531 D
Bio-Rad A Common Stock 08/25/2023 M 1,805(1) A $0 431,336 D
Bio-Rad A Common Stock 08/25/2023 F 895 D $381.78 430,441 D
Bio-Rad A Common Stock 08/25/2023 M 2,320(1) A $0 432,761 D
Bio-Rad A Common Stock 08/25/2023 F 1,151 D $381.78 431,610 D
Bio-Rad A Common Stock 08/25/2023 M 2,600(1) A $0 434,210 D
Bio-Rad A Common Stock 08/25/2023 F 1,290 D $381.78 432,920 D
Bio-Rad B Common Stock 08/25/2023 M 39,000 A $117.5 370,689 D
Bio-Rad B Common Stock 08/25/2023 F 25,389 D $381.78 345,300 D
Bio-Rad B Common Stock 12,900(2) I By Spouse
Bio-Rad B Common Stock 4,060,054(3) I By Blue Raven Partners, L.P.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(4) 08/25/2023 M 2,081 (5) (5) Bio-Rad A Common Stock 2,081 $0 6,245 D
Restricted Stock Units $0(4) 08/25/2023 M 1,266 (6) (6) Bio-Rad A Common Stock 1,266 $0 2,532 D
Restricted Stock Units $0(4) 08/25/2023 M 1,805 (7) (7) Bio-Rad A Common Stock 1,805 $0 1,805 D
Restricted Stock Units $0(4) 08/25/2023 M 2,320 (8) (8) Bio-Rad A Common Stock 2,320 $0 2,320 D
Restricted Stock Units $0(4) 08/25/2023 M 2,600 (9) (9) Bio-Rad A Common Stock 2,600 $0 0 D
Non-Qualified Stock Option (right to buy) $117.5 08/25/2023 M 39,000 (10) 09/11/2023 Bio-Rad B Common Stock 39,000 $0 0 D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. The reporting person disclaims beneficial ownership of these shares.
3. The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
4. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
5. On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments, of which 2,081 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant.
6. On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments, of which 1,266 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant.
7. On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments, of which 1,805 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant.
8. On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments, of which 2,320 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant.
9. On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments, of which 2,600 vested on August 25, 2023.
10. The option, representing a right to purchase a total of 39,000 shares, became exercisable in five equal annual installments beginning on September 11, 2014, which was the first anniversary of the date on which the option was granted.
/s/ Norman Schwartz 08/28/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Bio Rad Laboratories Charts.
Bio Rad Laboratories (NYSE:BIO.B)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Bio Rad Laboratories Charts.